Chemical formula: C₁₇H₁₆N₂O₃ Molecular mass: 254.284 g/mol
Eslicarbazepine and its metabolites stabilise the inactivated state of voltage-gated sodium channels, precluding their return to the activated state and thereby preventing repetitive neuronal firing. Therefore eslicarbazepine is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N03AF04 | Eslicarbazepine | N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AF Carboxamide derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| APTIOM Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| ZEBINIX Tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Eslicarbazepine is an active ingredient of these brands:
United States (US)
Canada (CA)
Cyprus (CY)
Estonia (EE)
Finland (FI)
France (FR)
Israel (IL)
Italy (IT)
Lithuania (LT)
Malta (MT)
Romania (RO)
Spain (ES)Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
